Global Health Ventures Inc., GHLV.OB
GHLV's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe.
GHLV recently completed the final formulation of X-Excite for the upcoming clinical trials in the United States.
Results of the interim clinical trials in Europe showed GHLV's X-Excite to appear in the blood rapidly and stay for longer time than the brand, Viagra(R). It is believed the longer presence of the drug in the blood may contribute to both buccal (sublingual) absorption and the gastric absorption.